💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Arrowhead Research Corporation (ARWR)
« Back to company indexARWR Chatter Timeline
Stock Ticker for ARWR
Most Active Tweeters for ARWR
| User | Tweets |
|---|---|
| @pt117cool | 27 |
| @BikeRieder | 21 |
| @gr8lakeinvestor | 14 |
| @MarkC53916729 | 9 |
| @truthtracer | 9 |
Recent Tweets for ARWR
 |
@RichUSA123 RT @Jarvis_Alerts: $ARWR [Arrowhead Pharmaceuticals]: HC Wainwright & Co. Initiates Coverage On Buy Announces Price Target $90 https://t.co… 1:05am |
 |
@tanavoi373 RT @truthtracer: @Partimefriend $AMGN demonstrates confidence bringing Olpasiran (AMG-890 formerly ARO-LPA) $ARWR TRiM™? to market. Not… May 8th 2021, 9:05pm |
 |
@truthtracer RT @Partimefriend: $ARWR AMGEN Clinical Research Medical Director - Cardiovascular.Medical Director to lead the Phase 3 Global Cardiovascul… May 8th 2021, 8:05pm |
|
@truthtracer @Partimefriend $AMGN demonstrates confidence bringing Olpasiran (AMG-890 formerly ARO-LPA) $ARWR TRiM™? to market… https://t.co/fKZmUI0d9Q May 8th 2021, 8:05pm |
 |
@PersimmonTI $ARWR Arrowhead’s near-term catalysts abound: ? https://t.co/Uj3hFwakLm May 8th 2021, 2:05pm |
 |
@Jarvis_Alerts $ARWR [Arrowhead Pharmaceuticals]: HC Wainwright & Co. Initiates Coverage On Buy Announces Price Target $90 https://t.co/39LFjfCvF9 May 8th 2021, 12:05pm |
 |
@Partimefriend $ARWR AMGEN Clinical Research Medical Director - Cardiovascular.Medical Director to lead the Phase 3 Global Cardiov… https://t.co/fdEU1rbuHh May 8th 2021, 11:05am |
 |
@youngbull_woe RT @BioBoyScout: @BioBoyScout reiterates $ARWR at $107 with a Strong Buy using a Risk-adjusted Discounted Cash Flow model with more detail… May 7th 2021, 10:05pm |
 |
@pt117cool Would love some $ARWR https://t.co/BsLvgviUNo to everyone. https://t.co/1K3EykdQa9 May 7th 2021, 6:05pm |
 |
@BioBoyScout @BioBoyScout reiterates $ARWR at $107 with a Strong Buy using a Risk-adjusted Discounted Cash Flow model with more… https://t.co/9PMJ3dp8Bw May 7th 2021, 6:05pm |
|
@pt117cool $ARWR-Ian4 hours ago MK-6482 in the phase 2 rd2p 120 daily dose had a 25% response rate and a median progression fr… https://t.co/jIefBjAdhr May 7th 2021, 5:05pm |
|
@auditor112017 @OxAnalyst This is a "long term" tox study. They might have to wait another 2-3yrs for this target. $arwr had simil… https://t.co/MdLs0Rkpzl May 7th 2021, 3:05pm |
 |
@Ba4Saso $ARWR waiting for short signal https://t.co/Z7hn4Qb2aY May 7th 2021, 2:05pm |
 |
@gr8lakeinvestor RT @BikeRieder: $ARWR ..discuss approvable endpoints with regulators in context of all the data we have generated. We’re nearing completio… May 7th 2021, 1:05pm |
|
@gr8lakeinvestor RT @BikeRieder: $ARWR AROAAT study changes: Javier S.M. at CCQ2: SEQUOIA was an adaptive design ph 2/3. Given the encouraging data we have… May 7th 2021, 1:05pm |
 |
@BikeRieder $ARWR ..discuss approvable endpoints with regulators in context of all the data we have generated. We’re nearing c… https://t.co/YAEa4o7L8E May 7th 2021, 12:05pm |
|
@BikeRieder $ARWR AROAAT study changes: Javier S.M. at CCQ2: SEQUOIA was an adaptive design ph 2/3. Given the encouraging data… https://t.co/iQ4Q3Z2m9n May 7th 2021, 12:05pm |
|
@pt117cool $ARWR - Coldlander36 minutes ago Sequoia trial completely revamped on clinical https://t.co/ptsGPi6Acx I am already… https://t.co/kpRZNk5jsd May 7th 2021, 12:05pm |
 |
@schauwersb RT @MarcJacksonLA: $ARWR B Riley Maintains Buy Rating On Arrowhead Pharmaceuticals, $106 PT https://t.co/Bx4olLiCiU May 6th 2021, 10:05pm |
 |
@Tickeron $ARWR's Aroon indicator drops into Downtrend on April 21, 2021. View odds for this and other indicators:… https://t.co/4jWue4CmJs May 6th 2021, 8:05pm |
 |
@MarcJacksonLA $ARWR B Riley Maintains Buy Rating On Arrowhead Pharmaceuticals, $106 PT https://t.co/Bx4olLiCiU May 6th 2021, 4:05pm |
 |
@ZacksSmallCap $ARWR: @ArrowheadPharma - Catalyst-Rich Summer Upcoming - https://t.co/8BcAwIVBBZ by @DavidBautz https://t.co/kwU90s0i0u May 6th 2021, 3:05pm |
|
@gr8lakeinvestor RT @BikeRieder: @Mcdivot06 $ARWR CEO said once or twice in the last half year, that NASH is multi factorial. Because of this, it’s difficu… May 6th 2021, 1:05pm |
|
@gr8lakeinvestor RT @BikeRieder: $ARWR CEO: -We will do some targeted no pun intended partnership (like with TAK, JNJ, AMGN) -We’ll continue that -No, we’r… May 6th 2021, 1:05pm |
|
@BikeRieder @Mcdivot06 $ARWR CEO said once or twice in the last half year, that NASH is multi factorial. Because of this, it’s… https://t.co/85uvpRxg2A May 6th 2021, 12:05pm |
 |
@Mcdivot06 @BikeRieder I agree that those 2 are the most likely for $ARWR to partner but I would rather keep HSD. May 6th 2021, 11:05am |
|
@Tickeron $ARWR enters a Downtrend as Momentum Indicator dropped below the 0 level on May 4, 2021. View odds for this and oth… https://t.co/sXPKKw55r4 May 6th 2021, 7:05am |
|
@BikeRieder $ARWR CEO: -We will do some targeted no pun intended partnership (like with TAK, JNJ, AMGN) -We’ll continue that -… https://t.co/JQDtVIvvOJ May 6th 2021, 4:05am |
 |
@buysidebiotech1 Expecting volume out of $ARWR in 8-12 mo. PT: $114.39 2/2/2021 May 6th 2021, 3:05am |
 |
@SauveRod RT @kshahi: Cough $ARWR Cough May 6th 2021, 3:05am |
|
@SauveRod RT @jonesallen234: There is been anedotal evidence of $ARWR having the superior delivery platform in terms of safety where indications over… May 6th 2021, 3:05am |
|
@SauveRod RT @1111DLH61: $arwr In case you missed it, APOC3 phase 3 (FCS patients) coming soon! May 6th 2021, 3:05am |
|
@Ba4Saso $ARWR waiting for buy signal https://t.co/otaxNww6IY May 5th 2021, 11:05pm |
 |
@CompoundNovice @gamechangercap I am not aware of any clinical results of RNAi in cancer. The ongoing phase 1 study of $ARWR target… https://t.co/PzaQ2I6pfi May 5th 2021, 10:05pm |
 |
@gamechangercap $DRNA $ARWR I think protein degradation is more exciting in the cancer space than rnai....rnai does have some uses… https://t.co/tPttN9Hm7R May 5th 2021, 10:05pm |
|
@CompoundNovice $ARWR upcoming catalysts for June and July This will be an eventful couple of months! https://t.co/GiP3itdItJ May 5th 2021, 9:05pm |
|
@pt117cool @kshahi @chiragontwtr $ARWR - Ever notice, that when they talk about ARWR now, it is either JNJ, AMGEN, TAK, PFE, V… https://t.co/cVb4low4QY May 5th 2021, 8:05pm |
|
@pt117cool @TheSliv @Steve_382 $ARWR = Always stated JNJ will know results on HBV before ARWR knows anything. Can hear top Man… https://t.co/xuBjXNPs9B May 5th 2021, 7:05pm |
|
@pt117cool RT @kshahi: @chiragontwtr If $ARWR gets a deal similar to Takeda from $PFE for any of their assets, they should take it IMO. They have 2-3… May 5th 2021, 7:05pm |
 |
@Steve_382 $ARWR I listened to the earnings CC. Sounded quite positive, but I was a little surprised to not hear much about HB… https://t.co/vYxNg9lmqL May 5th 2021, 7:05pm |
 |
@mhrob RT @Spreckels_Organ: $arwr $ions discontinuation of ENaC program for more promising pulm targets due to pre-clin LT tox finding. buried in… May 5th 2021, 7:05pm |
 |
@kshahi @chiragontwtr If $ARWR gets a deal similar to Takeda from $PFE for any of their assets, they should take it IMO. Th… https://t.co/FJJ8l2mAm3 May 5th 2021, 7:05pm |
|
@pt117cool RT @chiragontwtr: This is a big +ve for $ARWR. $IONS, the closest ENaC competitor in CF is down. https://t.co/Re02CBRsUo May 5th 2021, 7:05pm |
|
@pt117cool RT @FrankHulskof: $ARWR I guess the market thinks HCW knows better than Takeda. ??? https://t.co/WXZTU3w6Ye May 5th 2021, 7:05pm |
|
@pt117cool RT @ozzy_jozzy: @RNAiAnalyst Dirk, I’m a fan of both $ARWR and $AFMD, but while we’re on the topic of comparing completely different compan… May 5th 2021, 7:05pm |
|
@pt117cool RT @jonesallen234: @RNAiAnalyst You know who has not had this issue? $ARWR May 5th 2021, 7:05pm |
 |
@chiragontwtr This is a big +ve for $ARWR. $IONS, the closest ENaC competitor in CF is down. https://t.co/Re02CBRsUo May 5th 2021, 6:05pm |
 |
@jonesallen234 There is been anedotal evidence of $ARWR having the superior delivery platform in terms of safety where indications… https://t.co/dW7dohLrwH May 5th 2021, 6:05pm |
|
@jonesallen234 @RNAiAnalyst You know who has not had this issue? $ARWR May 5th 2021, 5:05pm |
 |
@Spreckels_Organ $arwr $ions discontinuation of ENaC program for more promising pulm targets due to pre-clin LT tox finding. buried… https://t.co/oKTLtx02Vn May 5th 2021, 4:05pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
